AbbVie (Ticker: ABBV) earnings reports
✅ Revenue
Financial estimates $11.936 billion → Result $12.31 billion (0.7% increase from the same period last year)
Financial estimates $11.936 billion → Result $12.31 billion (0.7% increase from the same period last year)
✅ Earnings per share
Financial estimates $2.26 → Result $2.31 (6.1% decrease)
Financial estimates $2.26 → Result $2.31 (6.1% decrease)
✅ Guidance
Upward revision of earnings per share
Estimate: $11.1 → Result: $11.13-$11.33
Upward revision of earnings per share
Estimate: $11.1 → Result: $11.13-$11.33
AbbVie's strategy is to offset the decline in Humira sales by Skyrizi and Rinvoq. Although the decrease in Humira sales was larger than expected, personally, I don't think it turned out too bad, so I am looking forward to the future.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
